Seagen and Astellas announce results from EV-302 study
Trial involves the use of Padcev and Keytruda among patients with certain types of urothelial cancer
Read Moreby John Pinching | Sep 25, 2023 | News | 0
Trial involves the use of Padcev and Keytruda among patients with certain types of urothelial cancer
Read Moreby John Pinching | Jun 28, 2023 | News | 0
Trial involved over 450 women across Europe, Turkey and Canada who were unsuitable for hormone therapy
Read Moreby John Pinching | Mar 21, 2023 | News | 0
Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer
Read Moreby Lucy Parsons | Jul 15, 2021 | News | 0
At the same time, Affinivax and Astellas revealed positive results from the Phase II trial of ASP3772
Read Moreby Lucy Parsons | Jun 10, 2021 | News | 0
Oral androgen receptor signalling inhibitor now approved to treat metastatic hormone-sensitive prostate cancer
Read Moreby Lucy Parsons | Mar 26, 2021 | News | 0
Marketing authorisation application is seeking approval for advanced urothelial cancer
Read Moreby Lucy Parsons | Oct 16, 2020 | News | 0
Companies will develop ultra-small implantable medical devices
Read Moreby Selina McKee | Aug 17, 2020 | News | 0
The final green light backs NHS use of the drug
Read Moreby Selina McKee | Jul 17, 2020 | News | 0
The drug is considered a cost-effective treatment for relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia
Read Moreby Anna Smith | Dec 6, 2019 | News | 0
Genetic regulation is set to become a fifth primary focus for the Japanese drugmaker, on top of its already existing business lines.
Read Moreby Anna Smith | Aug 7, 2019 | News | 0
The study will evaluate the drug in menopause related vasomotor symptoms, such as hot flashes and night sweats.
Read Moreby Anna Smith | Dec 18, 2018 | News | 0
The Prescription Medicines Code of Practice Authority (PMCPA) has announced that Astellas, Sunovion and Shield Therapeutics have all breached the Association of the British Pharmaceutical Industry’s Code of Practice.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479